José Juan Ruiz-Hernández

José Juan Ruiz-Hernández

Auto-generated profile, based on publicly available information

José Juan Ruiz-Hernández

Dpto Inmunología, Hosp. Univ. Dr. Negrin, Las Palmas de Gran Canaria, Spain

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 September 2022 in Journal of Experimental Medicine
Verified
Journal Article
Open access
PDF file
QZQian Zhang
Qian Zhang
MPMario Andrés Pizzorno
Mario Andrés Pizzorno
LMLisa Miorin
Lisa Miorin
PBPaul Bastard
Paul Bastard
AGAdrian Gervais
Adrian Gervais
JCJean-Laurent Casanova
Jean-Laurent Casanova
Autoantibodies neutralizing type I interferons (IFNs) can underlie critical COVID-19 pneumonia and yellow fever vaccine disease. We report here on 13 patients harboring autoantibodies neutralizing IFN-α2 alone (five patients) or with IFN-ω (eight patients) from a cohort of 279 patients (4.7%) aged 6–73 yr with critical influenza pneumonia. Nine and four patients had antibodies neutralizing high and low concentrations, respectively, of IFN-α2, and six and two patients had antibodies neutralizing high and low concentrations, respectively, of IFN-ω. The patients’ autoantibodies increased influenza A virus replication in both A549 cells and reconstituted human airway epithelia. The prevalence of these antibodies was significantly higher than that in the general population for patients 70 yr of age (3.1 vs. 4.4%, P = 0.68). The risk of critical influenza was highest in patients with antibodies neutralizing high concentrations of both IFN-α2 and IFN-ω (OR = 11.7, P = 1.3 × 10−5), especially those <70 yr old (OR = 139.9, P = 3.1 × 10−10). We also identified 10 patients in additional influenza patient cohorts. Autoantibodies neutralizing type I IFNs account for ∼5% of cases of life-threatening influenza pneumonia in patients <70 yr old.

1 October 2007 in European Journal of Gastroenterology & Hepatology
Verified
Journal Article
Closed access
JRJosé Juan Ruiz-Hernández
José Juan Ruiz-Hernández
MLMagdalena León-Mazorra
Magdalena León-Mazorra
ACAlicia Conde-Martel
Alicia Conde-Martel
JMJoaquin Marchena-Gomez
Joaquin Marchena-Gomez
MHMarion Hemmersbach-Miller
Marion Hemmersbach-Miller
PBPedro Betancor-León
Pedro Betancor-León
Goal To analyse the characteristics and mortality-related factors in a series of patients hospitalized for pyogenic liver abscess (PLA). Background Pyogenic liver abscesses are infrequent but potentially life threatening. Factors related to mortality have been less studied. Study The medical records of 84 patients, 56 men and 28 women, mean age of 64.4 years (SD: 14) who were hospitalized between 1992 and 2005 owing to a PLA were reviewed. The past medical history, clinical signs and symptoms, laboratory values, imaging studies, microbiological features, treatment, complications and mortality were recorded. Factors related to complications and mortality were analysed. Results One or more bacteria were isolated in 65 patients (77.4%), being Streptococcus spp. (40.5%), Escherichia coli (27.4%), Klebsiella spp. (14.3%) and anaerobics (17.9%) the most frequent isolates. Complications developed in 60.7% of the cases, the most common one being a right pleural effusion (34.5%). Mortality rate was 19% (95% confidence interval: 10–28%). Mortality was associated with age (P=0.005), a previous history of coronary heart disease (P=0.016), absence of fever (P=0.001), development of sepsis and/or septic shock (P<0.001), raise of bilirubin levels (P=0.004), a biliary (P=0.035), or cryptogenetic origin (P=0.039), infection owing to E. coli (P=0.01) or to Candida (P=0.009) and development of pneumonia (P<0.001). Logistic regression revealed sepsis and/or septic shock as an independent risk factor for mortality. Conclusions Mortality associated with PLA is high. The main risk factor for mortality is the development of sepsis and/or septic shock.

20 June 2014 in Critical Care
Verified
Journal Article
Open access
PDF file
Estefanía Herrera-RamosEstefanía Herrera-Ramos
Estefanía Herrera-Ramos
MLMarta López-Rodríguez
Marta López-Rodríguez
JRJosé Juan Ruíz-Hernández
José Juan Ruíz-Hernández
Juan P. HorcajadaJuan P. Horcajada
Juan P. Horcajada
LBLuis Borderías
Luis Borderías
CRCarlos Rodríguez-Gallego
Carlos Rodríguez-Gallego
Introduction: Inherited variability in host immune responses influences susceptibility and outcome of Influenza A virus (IAV) infection, but these factors remain largely unknown. Components of the innate immune response may be crucial in the first days of the infection. The collectins surfactant protein (SP)-A1, -A2, and -D and mannose-binding lectin (MBL) neutralize IAV infectivity, although only SP-A2 can establish an efficient neutralization of poorly glycosylated pandemic IAV strains. Methods: We studied the role of polymorphic variants at the genes of MBL (MBL2), SP-A1 (SFTPA1), SP-A2 (SFTPA2), and SP-D (SFTPD) in 93 patients with H1N1 pandemic 2009 (H1N1pdm) infection. Results: Multivariate analysis showed that two frequent SFTPA2 missense alleles (rs1965708-C and rs1059046-A) and the SFTPA2 haplotype 1A 0 were associated with a need for mechanical ventilation, acute respiratory failure, and acute respiratory distress syndrome. The SFTPA2 haplotype 1A 1 was a protective variant. Kaplan-Meier analysis and Cox regression also showed that diplotypes not containing the 1A 1 haplotype were associated with a significantly shorter time to ICU admission in hospitalized patients. In addition, rs1965708-C (P = 0.0007), rs1059046-A (P = 0.0007), and haplotype 1A 0 (P = 0.0004) were associated, in a dose-dependent fashion, with lower PaO2/FiO2 ratio, whereas haplotype 1A 1 was associated with a higher PaO2/FiO2 ratio (P = 0.001). Conclusions: Our data suggest an effect of genetic variants of SFTPA2 on the severity of H1N1pdm infection and could pave the way for a potential treatment with haplotype-specific (1A 1 ) SP-A2 for future IAV pandemics.

4 August 2016 in European Journal of Clinical Microbiology & Infectious Diseases
Verified
Journal Article
Closed access
PDF file
MLM. López-Rodríguez
M. López-Rodríguez
Estefanía Herrera-RamosEstefanía Herrera-Ramos
Estefanía Herrera-Ramos
JVJordi Solé Violán
Jordi Solé Violán
JRJ. J. Ruíz-Hernández
J. J. Ruíz-Hernández
LBLuis Borderías
Luis Borderías
CRC. Rodríguez-Gallego
C. Rodríguez-Gallego

1 May 2018 in Journal of Clinical Immunology
Verified
Journal Article
Closed access
PDF file
ISIthaisa Sologuren
Ithaisa Sologuren
MMMaría Teresa Martínez-Saavedra
María Teresa Martínez-Saavedra
JSJordi Solé-Violán
Jordi Solé-Violán
EJEdgar de Borges de Oliveira Jr
Edgar de Borges de Oliveira Jr
EBEva Betancor
Eva Betancor
CRCarlos Rodríguez-Gallego
Carlos Rodríguez-Gallego

29 May 2019 in Irish Journal of Medical Science (1971 -)
Verified
Journal Article
Closed access
PDF file
JRJose Juan Ruiz-Hernández
Jose Juan Ruiz-Hernández
ACAlicia Conde-Martel
Alicia Conde-Martel
MSMiriam Serrano-Fuentes
Miriam Serrano-Fuentes
MHMarta Hernández-Meneses
Marta Hernández-Meneses
AMAlejandro Merlán-Hermida
Alejandro Merlán-Hermida
JMJoaquín Marchena-Gómez
Joaquín Marchena-Gómez